Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?
详细信息 查看全文
- 作者：Rhiannon Koirala ; David Gyorki
- 关键词：Melanoma ; Immunotherapy ; Perioperative ; Tumour ; infiltrating lymphocytes ; Immunosurveillance ; Checkpoint blockade
- 刊名：Current Anesthesiology Reports
- 出版年：2015
- 出版时间：September 2015
- 年：2015
- 卷：5
- 期：3
- 页码：257-267
- 全文大小：823 KB
- 参考文献：Papers of particular interest, published recently, have been highlighted as: 鈥?Of importance 鈥⑩€?Of major importance1.Thomas L. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959.
2.Burnet M. The processes of control. Br Med J. 1957;1:779鈥?6.PubMed Central PubMed View Article
3.Cheever MA, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323鈥?7.PubMed View Article
4.Porta MD, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology. 2005;68(2鈥?):276鈥?4.PubMed View Article
5.Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685鈥?11.PubMed View Article
6.Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269鈥?1.PubMed View Article
7.Gyorki DE, et al. The delicate balance of melanoma immunotherapy. Clin Transl Immunology. 2013;2(8):e5.PubMed Central PubMed View Article
8.鈥?Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity鈥檚 roles in cancer suppression and promotion. Science. 2011;331(6024):1565鈥?0. This review defines the role of immune editing in tumorigenesis.
9.Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942鈥?.PubMed View Article
10.Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev. 2014;259(1):245鈥?8.PubMed Central PubMed View Article
11.Gattinoni L, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383鈥?3.PubMed Central PubMed View Article
12.Naito Y, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491鈥?.PubMed
13.Piersma SJ, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67(1):354鈥?1.PubMed View Article
14.Nakano O, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132鈥?.PubMed
15.Mahmoud SM, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949鈥?5.PubMed View Article
16.Fortes C, et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. J Transl Med. 2015;13:2066.View Article
17.Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105鈥?3.PubMed View Article
18.Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10(5):588鈥?4.PubMed View Article
19.Antony PA, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591鈥?01.PubMed Central PubMed View Article
20.Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007;8(3):277鈥?4.PubMed View Article
21.Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804鈥?1.PubMed View Article
22.Chaudhary B, et al. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther. 2014;14(7):931鈥?5.PubMed View Article
23.Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev. 2014;33(4):1025鈥?1.PubMed View Article
24.Kohrt HE, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2(9):e284.PubMed Central PubMed View Article
25.Gooden MJ, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93鈥?03.PubMed Central PubMed View Article
26.鈥?Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960鈥?. This seminal paper highlighted the key prognostic significance of tumour infiltration by immune cells.
27.Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305鈥?4.PubMed View Article
28.Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51鈥?0.PubMed Central PubMed
29.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252鈥?4.PubMed View Article
30.Karasar P, Esendagli G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat. 2014;145(3):605鈥?4.PubMed View Article
31.Velu V, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206鈥?0.PubMed Central PubMed View Article
32.Flies DB, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84(4):409鈥?1.PubMed Central PubMed
33.Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089鈥?6.PubMed
34.Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455鈥?5.PubMed Central PubMed View Article
35.Taube JM, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.PubMed Central PubMed View Article
36.Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307鈥?4.PubMed View Article
37.Ghiotto M, et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol. 2010;22(8):651鈥?0.PubMed Central PubMed View Article
38.Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26(3鈥?):373鈥?00.PubMed View Article
39.Hagemann T, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25(8):1543鈥?.PubMed View Article
40.Eccles SA, Alexander P. Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature. 1974;250(5468):667鈥?.PubMed View Article
41.Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16(1):53鈥?5.PubMed View Article
42.Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011;30(1):125鈥?0.PubMed View Article
43.Zea AH, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65(8):3044鈥?.PubMed
44.de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol. 1993;150(11):4754鈥?5.PubMed
45.Gallina G, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777鈥?0.PubMed Central PubMed View Article
46.Parmiani G, et al. Cytokines in cancer therapy. Immunol Lett. 2000;74(1):41鈥?.PubMed View Article
47.Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy. 2009;1(1):109鈥?7.PubMed View Article
48.鈥?Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107鈥?1. This seminal paper highlights the role of the immune response in shaping an evolving tumour.
49.Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991鈥?.PubMed View Article
50.Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007;7:4.PubMed Central PubMed
51.Siddiqui SA, et al. Tumor-infiltrating Foxp3-CD4+ CD25聽+聽T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13(7):2075鈥?1.PubMed View Article
52.Kolbeck PC, et al. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. Mod Pathol. 1992;5(4):420鈥?.PubMed
53.Templeton AJ, McNamara MG, 艩eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.PubMed View Article
54.Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23(1):31鈥?.PubMed View Article
55.Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834鈥?6.PubMed Central PubMed View Article
56.Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903鈥?.PubMed View Article
57.Teng MW, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 2012;72(16):3987鈥?6.PubMed Central PubMed View Article
58.Mittal D, et al. New insights into cancer immunoediting and its three component phases鈥揺limination, equilibrium and escape. Curr Opin Immunol. 2014;27:16鈥?5.PubMed Central PubMed View Article
59.Rabson A. Really essential medical immunology. 2nd ed. Oxford UK: Blackwell Publishing Ltd.; 2005.
60.Vesely MD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235鈥?1.PubMed View Article
61.Fourcade J, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009;182(9):5240鈥?.PubMed Central PubMed View Article
62.Egberts F, et al. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol. 2014;25(1):246鈥?0.PubMed View Article
63.Quaglino P, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21(2):409鈥?4.PubMed View Article
64.Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23(6):488鈥?6.
65.鈥?Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485鈥?2. This was the first study to identify a use T cell modulation to achieve a tumour response.
66.Atkins MB, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11鈥?.PubMed
67.鈥?Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56鈥?1. This review provides clear perspective of a rapidly evolving field.
68.Azuma M, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366(6450):76鈥?.PubMed View Article
69.Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459鈥?5.PubMed View Article
70.Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009;157(1):9鈥?9.PubMed Central PubMed View Article
71.鈥⑩€?Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517鈥?6. This was the first trial to demonstrate a survival benefit in patients with metastatic disease in the first line setting.
72.Prieto PA, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039鈥?7.PubMed Central PubMed View Article
73.Yang JC, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825鈥?0.PubMed Central PubMed View Article
74.Hodi FS, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105(8):3005鈥?0.PubMed Central PubMed View Article
75.van den Eertwegh AJ, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509鈥?7.PubMed View Article
76.Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537鈥?4.PubMed Central PubMed View Article
77.Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015.
78.Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med 2015.
79.Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189鈥?9.PubMed Central PubMed View Article
80.Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568鈥?1.PubMed Central PubMed View Article
81.Shahabi V, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38(1):90鈥?.PubMed View Article
82.Knisely JP, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227鈥?3.PubMed View Article
83.Postow MA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925鈥?1.PubMed Central PubMed View Article
84.Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205鈥?6.PubMed View Article
85.Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228鈥?7.PubMed View Article
86.Hamid O. Kinetics of response to ipilimumab (MDX-010) in patints with stage 3/4 melanoma. J Clin Oncol. 2007;25(18S):8252.
87.Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412鈥?0.PubMed View Article
88.Postow MA. Current options and future directions in the systemic treatment of metastatic melanoma. J Community Support Oncol. 2014;12(1):20鈥?.PubMed
89.Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709鈥?8.PubMed View Article
90.Phan GQ, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19(15):3477鈥?2.PubMed
91.Carthon BC, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861鈥?1.PubMed Central PubMed View Article
92.Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013;30(Suppl):S32鈥?0.PubMed Central PubMed View Article
93.Hiller J, Brodner G, Gottschalk A. Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. Best Pract Res Clin Anaesthesiol. 2013;27(4):427鈥?9.PubMed View Article
94.Horowitz M, et al. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015;12(4):213鈥?6.PubMed View Article
95.Exadaktylos AK, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660鈥?.PubMed Central PubMed View Article
96.Kim R, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527鈥?6.PubMed View Article
97.Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother. 1996;43(1):1鈥?.PubMed
98.Landmann R. Beta-adrenergic receptors in human leukocyte subpopulations. Eur J Clin Invest. 1992;22(Suppl 1):30鈥?.PubMed
99.Ben-Eliyahu S, et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. NeuroImmunoModulation. 2000;8(3):154鈥?4.PubMed View Article
100.Martinet L, Poupot R, Fournie JJ. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Immunol Lett. 2009;124(1):1鈥?.PubMed View Article
101.Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231鈥?.PubMed View Article
102.Costa C, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55(6):429鈥?4.PubMed Central PubMed View Article
103.Usman MW, et al. Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta. 2015;1855(2):254鈥?3.PubMed
104.Sloan EK, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042鈥?2.PubMed Central PubMed View Article
105.Lutgendorf SK, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514鈥?1.PubMed
106.Magnon C, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361.PubMed View Article
107.van der Bij GJ, et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009;249(5):727鈥?4.PubMed View Article
108.Roche-Nagle G, et al. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer. 2004;91(2):359鈥?5.PubMed Central PubMed
109.Thaker PH, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939鈥?4.PubMed View Article
110.Zheng Y, et al. Application of perioperative immunonutrition for gastrointestinal surgery: a meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2007;16(Suppl 1):253鈥?.PubMed
111.Marik PE, Zaloga GP. Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature. J Parenter Enteral Nutr. 2010;34(4):378鈥?6.View Article
112.Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med. 1996;334(19):1209鈥?5.PubMed View Article
113.Beilin B, et al. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology. 1998;89(5):1133鈥?0.PubMed View Article
114.Frank SM, et al. The catecholamine, cortisol, and hemodynamic responses to mild perioperative hypothermia. A randomized clinical trial. Anesthesiology. 1995;82(1):83鈥?3.PubMed View Article
115.Kavanagh T, Buggy DJ. Can anaesthetic technique effect postoperative outcome? Curr Opin Anaesthesiol. 2012;25(2):185鈥?8.PubMed View Article
116.Cata JP, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110(5):690鈥?01.PubMed Central PubMed View Article
117.Schriemer PA, Longnecker DE, Mintz PD. The possible immunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology. 1988;68(3):422鈥?.PubMed View Article
118.Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033.
119.Krarup PM, et al. Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg. 2014;259(5):930鈥?.PubMed View Article
120.Mirnezami A, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253(5):890鈥?.PubMed View Article - 作者单位：Rhiannon Koirala (1)
David Gyorki (1)
1. Peter MacCallum Cancer Centre, Locked Bag 1 A鈥橞eckett St, East Melbourne, VIC, 8006, Australia - 刊物主题：Anesthesiology;
- 出版者：Springer US
- ISSN：2167-6275
文摘
The immune system involves a complex interplay between the host and its environment. Cancer cell growth requires immune tolerance in order to avoid rejection, this occurs despite tumour recognition by innate and adaptive immune components. As our understanding of the immune system and immunosurveillance improves, so too does our understanding of the complex mechanisms involved in tumour growth and local immunosuppression. Recent advances in tumour immunology and immunotherapy have lead to the development of an array of novel therapies with unprecedented efficacy in multiple tumour types, particularly in patients with metastatic melanoma. This review describes these advances in our understanding of the tumour-host interaction and discusses potential implications for patient care in the perioperative period.